Healthcare
Dr. Peter Grinspoon’s Recommendations On Using Cannabis To Manage Chronic Pain
In a recent interview, he expressed his finding that “people almost exclusively talk about their quality of life getting better when using cannabis as compared to opiates.”
In the field of medical cannabis, not many issues have been hotly debated as that of cannabis in relation to opioid addiction. (Is cannabis the ultimate exit drug for opioid addiction?) Given that millions of Americans are hooked on opioids and struggling to find an exit, the controversy is not surprising.
For a number of years, a 2014 “review of death certificates” served as a landmark study proving that opioid-related overdose deaths were reduced in states with legal cannabis programs. This study has been cited time and again when the issue of cannabis and opioids comes up. However, a subsequent review showed that this correlation weakens when you look at studies extending beyond the 2014 period.
A 2017 study found a minimal reduction in opioid-related overdose deaths in states with legal adult-use cannabis programs. However, no significant correlation was observed in a 2020 study. While it appears that post-2014 evidence is jumbled up, having the right policies in place could significantly reduce opioid-related harms.
Peter Grinspoon is a medical doctor who is both a thought leader and pacesetter in the field of medical cannabis. He’s authored a book, “Free Refills,” that narrates his struggle with opioid addiction and how has been able to break free. His second book, “Seeing through the smoke,” is in the pipeline. He is an internist as well as a medical cannabis physician working at the Massachusetts General Hospital. He is also a Harvard Medical School instructor. He is an acclaimed speaker on matters of cannabis and addiction.

Speaking to Filter Magazine, he expressed his finding that “people almost exclusively talk about their quality of life getting better when using cannabis as compared to opiates.”
Dr. Grinspoon believes that medical cannabis is a solution to the opioid crisis and recommends the following strategies for recommending cannabis for chronic pain:
- Start new chronic pain patients on cannabis instead of offering NSAIDs or opioids to reduce the risk of adverse effects that come with long-term use of these drugs
- To gradually transition chronic pain patients from opioids to cannabis voluntarily
- To use cannabis and opioids together to manage chronic pain
- To use cannabis to manage opioid addiction
In 2020, there were 91,799 opioid-related overdose deaths in the United States. Other complications from opioids include bone thinning, physical dependence, and tolerance. While chronic cannabis use may also trigger physical dependence, it’s hardly ever problematic.
Cannabis and opioids work on different systems in the body, but they have overlapping effects, especially analgesia. Cannabis, however, does not cause respiratory depression and hence the risk for cannabis-related overdose deaths is theoretically nil. For mild to moderate pain, opioids might be a safer and more effective alternative for pain management, especially when long-term care is in the picture. But again, qualified prescribing doctors are best placed to advise on a case-by-case basis.
Education News
AIIMS Gorakhpur Reservation Controversy: FIR Alleges Fake OBC Certificate Used Despite ₹80 Lakh Income
A major controversy has emerged at AIIMS Gorakhpur after allegations surfaced that reservation benefits were misused to secure a postgraduate medical seat. A criminal case has been registered against former AIIMS Gorakhpur Executive Director Dr. G.K. Pal and his son, Dr. Oro Prakash Pal, over the alleged use of a forged Other Backward Class (OBC) Non-Creamy Layer certificate for admission to an MD course.
The case has triggered widespread debate within medical and administrative circles, raising serious questions about transparency and oversight in admissions to premier medical institutions.
FIR Filed on Court’s Direction
The First Information Report (FIR) was registered at the AIIMS police station following directions from Chief Judicial Magistrate Tvishi Srivastava. According to the complaint, the alleged offence took place on August 30, 2024, when forged documents were purportedly used to obtain an MD seat under the OBC reservation quota.
Sources indicate that the matter was subsequently brought to the attention of the Union Ministry of Health, prompting internal reviews and administrative action.
Alleged Income Far Above Eligibility Threshold
Central to the allegations is the claim that Dr. G.K. Pal and his wife Parvati Pal have a combined annual income exceeding ₹80 lakh. Under existing reservation rules, families with such income levels are not eligible for OBC Non-Creamy Layer benefits.
Following the emergence of the controversy, Dr. Pal was first removed from his position at AIIMS Gorakhpur and later relieved of responsibilities at AIIMS Patna. He is currently posted at JIPMER Puducherry. With the registration of the FIR, officials suggest that further legal and departmental action may follow, depending on the outcome of the investigation.
Complaint Highlights Systemic Concerns
The complaint was filed by Ashutosh Kumar Mishra, a resident of Divyanagar in the Cantonment area. He alleged that the events related to the case occurred between January and September 2024. The complainant argued that misuse of reservation provisions by individuals in senior positions undermines the integrity of public institutions and erodes trust in the medical education system.
The case has reignited concerns over whether verification mechanisms for reservation certificates are robust enough, particularly in high-stakes admissions.
Impact on Medical Community
The allegations have sent shockwaves through the medical fraternity. Experts believe that if the claims are substantiated, the case could prompt a broader review of admission procedures and lead to stricter scrutiny of category certificates across institutions like AIIMS.
Authorities have stated that all relevant documents will be carefully examined before taking further steps. The outcome of the investigation is expected to have far-reaching implications for accountability and compliance in medical admissions.
Questions Await Answers
As the probe continues, several key issues remain unresolved: whether reservation norms were deliberately violated, how verification processes failed, and whether similar cases may surface in the future. For now, the focus remains on the investigation and its potential consequences.
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Business
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business2 years agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business2 years agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business2 years agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business2 years agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business2 years agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business2 years agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business2 years agoCan Cannabis Help Seasonal Depression
-
Blogs3 years agoCannabis Art Is Flourishing On Etsy
